Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Mazdutide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ph 3 Mazdutide Obesity Study Published in NEJM
    Ph 3 Mazdutide Obesity Study Published in NEJM

    25 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/phase-3-clinical-study-of-mazdutide-in-chinese-adults-with-overweight-or-obesity-glory-1-published-in-the-new-england-journal-of-medicine-nejm-302464859.html

    PR NEWSWIRE
    25 May 2025
    Share Share
    GLORY-3: Second Phase 3 Study of Mazdutide vs Semaglutide Begins
    GLORY-3: Second Phase 3 Study of Mazdutide vs Semaglutide Begins

    15 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/second-head-to-head-phase-3-study-of-mazdutide-versus-semaglutide-completes-first-participant-dosing-in-adults-in-china-with-overweight-or-obesity-accompanied-fatty-liver-disease-glory-3-302456545.html

    PR NEWSWIRE
    15 May 2025
    Share Share
    Innovent's Mazdutide Shows Superiority Over Dulaglutide In Diabetes Trial
    Innovent's Mazdutide Shows Superiority Over Dulaglutide In Diabetes Trial

    11 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/head-to-head-superiority-over-dulaglutide-innovents-phase-3-clinical-trial-dreams-2-of-mazdutide-in-chinese-patients-with-type-2-diabetes-were-orally-presented-at-easd-2024-302244860.html

    PR NEWSWIRE
    11 Sep 2024
    Share Share
    Innovent Annouces Multiple Clinical Study Results of Mazdutide
    Innovent Annouces Multiple Clinical Study Results of Mazdutide

    01 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/innovent-annouces-multiple-clinical-study-results-of-mazdutide-to-be-presented-at-the-easd-2024-302235586.html

    PR NEWSWIRE
    01 Sep 2024
    Share Share
    Innovent bags another phase 3 win in China for next-gen Lilly GLP-1 drug
    Innovent bags another phase 3 win in China for next-gen Lilly GLP-1 drug

    23 Jul 2024

    // BIOSPACE

    https://www.biospace.com/drug-development/innovents-lilly-partnered-type-2-diabetes-drug-aces-phase-iii-in-china-inches-closer-to-approval

    BIOSPACE
    23 Jul 2024
    Share Share
    Innovent Updates Data From Mazdutide GLORY-1 Study And Biomedicine Pipeline
    Innovent Updates Data From Mazdutide GLORY-1 Study And Biomedicine Pipeline

    27 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/innovent-provides-interpretation-and-updates-on-clinical-data-from-mazdutide-glory-1-study-and-general-biomedicine-pipeline-302184351.html

    PR NEWSWIRE
    27 Jun 2024
    Share Share